Pardeep Heir
Associate
Norton Rose Fulbright Canada LLP
Related services and key industries
Biography
Pardeep Heir practises intellectual property law with an emphasis on pharmaceutical patent litigation.
Dr. Heir joined our Toronto office as a summer student in 2018 and returned to article with us in 2019-2020. During his articles, Dr. Heir was seconded to GlaxoSmithKline Inc. where he gained valuable experience with commercial, employment, intellectual property and regulatory matters.
During law school Dr. Heir interned at a non-profit organization where he addressed proposed regulatory changes by Health Canada. Before his legal career, Dr. Heir worked as a scientific associate at a cancer research centre. He studied post-translational modifications of proteins and signal transduction pathways with the goal of targeting aberrations using therapeutic modalities. Dr. Heir's research has been published in peer-reviewed scientific journals, and he has presented his research at international scientific conferences.
Professional experience
Collapse all- J.D., University of Toronto, 2019
- Ph.D., University of Toronto, 2015
- B.Sc. (Hons.), York University, 2008
- Ontario 2020
- Canadian Law Awards 2022, Commercial Litigation Case of the Year Excellence Awardee for Pharmascience Inc. v. Pfizer Canada ULC
- Co-author, "c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein," Molecular Cancer Research, 2020
- Co-author, "CIC protein instability contributes to tumorigenesis in glioblastoma," Nature Communications, 2019
- First author, "Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling," The Journal of Biological Chemistry, 2016
- First author, "Hydroxylation-Dependent Interaction of Substrates to the Von Hippel-Lindau Tumor Suppressor Protein (VHL)," Methods in Molecular Biology, 2016
- Co-author, "Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis," Nature Communications, 2015
- Co-author, "Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway," Oncogene, 2015
- Co-author, "Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation," Proceedings of the National Academy of Sciences of the United States of America, 2014
- Co-author, "SOCS-1 mediates ubiquitylation and degradation of GM-CSF receptor," PLoS One, 2013
- First author, "DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase," Molecular and Cellular Biology, 2013
- Co-author, "Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1," Proceedings of the National Academy of Sciences of the United States of America, 2012
- Co-author, "Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia," Nature Medicine, 2011
- Co-author, "Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma," The American Journal of Pathology, 2011